Skip to main content
SOMNOMED LIMITED logo

SOMNOMED LIMITED — Investor Relations & Filings

Ticker · SOM ISIN · AU000000SOM1 LEI · 529900NFR8QFOLJGP577 ASX Manufacturing
Open in API
Filings indexed 982 across all filing types
Latest filing 2024-02-21 Board/Management Inform…
Country AU Australia
Listing ASX SOM

About SOMNOMED LIMITED

https://somnomed.com

SomnoMed Limited specializes in the development and manufacture of diagnostic and treatment solutions for sleep-related breathing disorders, primarily obstructive sleep apnea (OSA). The company is recognized for its Continuous Open Airway Therapy (COAT), which utilizes custom-fitted oral appliances to maintain an open airway during sleep. Its flagship product line, SomnoDent, offers a range of mandibular advancement devices designed to improve patient compliance and comfort compared to traditional continuous positive airway pressure (CPAP) therapy. SomnoMed focuses on clinical research and technological innovation to provide effective, non-invasive alternatives for patients suffering from mild to moderate OSA and snoring. The company serves a global market, collaborating with sleep dentists and physicians to deliver personalized treatment options that enhance long-term health outcomes and quality of life for individuals with sleep-disordered breathing.

Recent filings

Filing Released Lang Actions
Appointment of Co-CEO's 2 pages 145.1KB
Board/Management Information Classification · 95% confidence The document is an announcement from the Board of Directors of SomnoMed Limited regarding the appointment of two new Co-CEOs. It details the backgrounds of the new executives, the outgoing CEO's resignation, and the company's strategic outlook. It also mentions the upcoming release of half-year results but does not contain any financial statements or detailed financial data itself. The document is focused on management changes and leadership structure rather than financial reporting or other regulatory filings. Therefore, it fits best under the category of Board/Management Information (MANG). The document length (5580 characters) and content confirm it is not a brief report publication announcement or a full financial report.
2024-02-21 English
Material terms of employment agreements Co-CEO's 2 pages 125.0KB
Board/Management Information Classification · 95% confidence The document contains detailed summaries of employment agreements for two Co-CEOs, including terms of remuneration, bonuses, option grants, termination entitlements, and post-employment restraints. There is no indication of financial statements, audit information, regulatory certifications, or announcements related to voting, dividends, or capital changes. The content focuses on management employment terms, which aligns with announcements or disclosures about changes in senior management or executive appointments. Therefore, the document is best classified as Board/Management Information (MANG). The document length (8611 characters) and detailed content support this classification rather than a brief announcement or a regulatory filing.
2024-02-21 English
Final Director's Interest Notice 2 pages 875.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including shares and options, and notes the date the director ceased to be a director. This is a report of personal share transactions and holdings by a company director, which aligns with the definition of Director's Dealing filings. The document length is short and focused solely on director share interests, with no financial results or other report content. Therefore, the appropriate classification is Director's Dealing (DIRS).
2024-02-21 English
Notification of cessation of securities - SOM 4 pages 14.8KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse or cessation of certain securities (options) for SomnoMed Limited. It provides specific information about the securities that have ceased, the reasons for cessation, and the updated issued capital following these changes. The document is a formal announcement related to changes in the company's securities, specifically the cessation of certain options. It does not contain financial statements, management discussion, or detailed financial results. It is not an annual or interim report, nor an earnings release or audit report. It is also not a report publication announcement or a certification. The document fits the category of a Regulatory Filing (RNS) as it is a formal regulatory announcement to the ASX about changes in securities status that does not fit into more specific categories like capital changes or share issues (which usually involve new shares or capital raising). The document length is 4076 characters, which is relatively short and consistent with a regulatory announcement. Therefore, the best classification is Regulatory Filings (RNS).
2024-02-21 English
Quarterly Activities Report 4 pages 295.9KB
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly activities report for the period ended 31 December 2023 (Q2 FY24) from SomnoMed Limited. It contains detailed financial data including revenue figures for Q2 and the first half of FY24, operational comments, cash flow information, and updates on manufacturing and regulatory filings. The presence of actual financial statements and substantive financial data for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document is 8078 characters long, which is sufficient to be a full report rather than a brief announcement. There is no indication that this is an earnings release (which would be more summary), nor an annual report or other category. Therefore, the correct classification is Interim / Quarterly Report (IR). Q2 2024
2024-01-29 English
Quarterly Appendix 4C Cash Flow Report 6 pages 271.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B' and contains detailed quarterly cash flow statements including operating, investing, and financing activities. It includes specific quarterly and year-to-date financial data, reconciliation of cash and cash equivalents, financing facilities, and estimated cash available for future operating activities. The document also contains a compliance statement and notes referencing Australian Accounting Standards and ASX Listing Rules. The length of the document (12,178 characters) and the detailed financial data confirm it is a substantive financial report for a quarter, not merely an announcement or certification. This matches the definition of an Interim / Quarterly Report (IR). Q2 2024
2024-01-29 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.